(Corrects media packaging code; no changes to text)
Jan 29 (Reuters) - Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Retirement savings play a crucial role in securing financial stability in your golden years. For those aiming high, being in the top 3% of retirees in terms of savings enhances comfort and offers greater financial freedom. Using data from the Federal Reserve's Survey of Consumer Finances, a 2024 survey by the Employee Benefit Research Institute, reveals that individuals with over $1 million in retirement accounts rank in the top 3% of retirees. Only 3.2% of retirees have surpassed the $1 million
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
The $50 million purchase could turn into Nvidia's biggest investment.
These proven wealth builders could be exactly what you're searching for right now.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
These three tech stocks look like reliable long-term winners.
The number probably isn't anywhere near what you think it is.
You'll get dividends and more with these great stocks.
The tobacco giant will soon be allowed to sell a proven product in a proven market.